Last updated: May 6, 2026
Parsabiv (etelcalcetide): Clinical Trials Update, Market Analysis, and Revenue Projection (2026–2036)
What is Parsabiv and where is it used?
Parsabiv (etelcalcetide) is an injectable calcimimetic indicated for:
- Secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
- Reduction of elevated parathyroid hormone (PTH) in the FDA-labeled population via calcium-sensing receptor modulation.
Commercially, Parsabiv is a late-competitive entrant to the calcimimetic class that competes primarily with cinacalcet and cinacalcet alternatives (including other branded calcimimetics where applicable by geography) and, more broadly, with standard-of-care mineral bone disorder management.
Regulatory status (anchor facts)
- FDA approval: 2017 (first US commercial launch in the calcimimetic class for etelcalcetide).
- Formulation and administration: IV administration in hemodialysis (market model depends on payer and dialysis-unit dosing cadence).
What are the current clinical-trials signals for etelcalcetide?
No complete, source-verified live-trial update set is available in the provided context to compile an accurate “current status” snapshot (trial IDs, phase, enrollment, results, readouts, and dates). Under the operating rules, this prevents a complete and accurate clinical trials update.
Result: No trial-by-trial update is provided.
How does Parsabiv position competitively in the calcimimetic market?
Parsabiv participates in the sHPT segment where dosing is routine in hemodialysis workflows and therapy persistence is shaped by:
- Biochemical control targets (PTH suppression) and dialysis center adoption.
- Safety and tolerability (hypocalcemia risk management affects payer and clinic protocols).
- Administration logistics (IV integration vs oral calcimimetics).
- Switching dynamics between cinacalcet and etelcalcetide, and within-equipment protocols.
Key commercial implications
- Hemodialysis concentration is the demand base. Uptake tends to correlate with centers where nephrology governance standardizes medication formularies.
- Since cinacalcet is largely generic in many markets, pricing pressure is a structural feature; branded differentiation must translate into measurable reductions in adverse events or treatment changes to sustain premium pricing.
- Biosimilar-style competitive logic is not applicable; the competitive set is molecule-based with generic headwinds.
What is the Parsabiv market sizing basis for projections?
A robust projection requires numeric inputs that are not present in the supplied context (country coverage, treatment prevalence, price net of rebates, channel mix, and branded vs generic penetration). Under the operating rules, this blocks a complete numeric market sizing and forecast.
Result: No numeric market sizing or revenue projection is provided.
What revenue model would be used if inputs are available?
A parsimonious, investor-grade model for etelcalcetide in sHPT typically uses four layers:
-
Patient base
- Adult CKD on hemodialysis with sHPT meeting treatment initiation criteria
- Switch-ready cohort (patients on cinacalcet with inadequate control or tolerability issues)
-
Penetration and share
- Dialysis-unit adoption rate for etelcalcetide
- Persistence and dose intensity assumptions
-
Commercial pricing
- List price and net price after rebates
- IV administration cost offsets are usually not separable in public datasets; models rely on payer net price
-
Dynamics
- Generic erosion (cinacalcet availability)
- Margin effects from rebates and contracting
- Any label expansion or new regimen evidence (if present)
Why this matters for etelcalcetide specifically
- The highest sensitivity variables are net price and persistence under generic competition, because patient counts grow slowly relative to uptake shifts inside dialysis programs.
What investment-grade outlook can be stated with the information provided?
Only non-quantitative, non-cited statements can be supported, and the prompt requires a clinical update and numeric market analysis and projection. The operating constraints prohibit producing incomplete or unsubstantiated numbers.
Result: No market projection is generated.
Key Takeaways
- Parsabiv (etelcalcetide) is approved for secondary hyperparathyroidism in adults with CKD on hemodialysis, administered in hemodialysis workflows.
- The request for a clinical trials update cannot be completed without a source-verified live trial set.
- The request for market analysis and revenue projection cannot be completed without numeric inputs (pricing, adoption/penetration, and patient base) supported by sources.
FAQs
1) What is Parsabiv’s indication?
Parsabiv is indicated for secondary hyperparathyroidism in adult CKD patients on hemodialysis to reduce elevated PTH.
2) What competition does Parsabiv face?
It competes in calcimimetic therapy for sHPT, primarily against cinacalcet and treatment approaches used in dialysis mineral bone disorder management.
3) What most drives Parsabiv commercial performance?
In practice, performance hinges on dialysis-unit adoption, persistence, and net pricing under generic cinacalcet pricing pressure.
4) Can I get a trial-by-trial status update here?
Not under the current constraints because a complete, source-verified trials dataset is not included in the provided information.
5) Is a quantified revenue projection possible here?
Not under the current constraints because numeric market inputs and source-backed assumptions are not provided.
References (APA)
[1] U.S. Food and Drug Administration. (2017). FDA approval information for Parsabiv (etelcalcetide).
[2] FDA. Parsabiv prescribing information (accessed via FDA label repositories).
